Coherent Control of Stationary Light Pulses

We present a detailed analysis of the recently demonstrated technique to generate quasi-stationary pulses of light [M. Bajcsy {\it et al.}, Nature (London) \textbf{426}, 638 (2003)] based on electromagnetically induced transparency. We show that the use of counter-propagating control fields to retrieve a light pulse, previously stored in a collective atomic Raman excitation, leads to quasi-stationary light field that undergoes a slow diffusive spread. The underlying physics of this process is identified as pulse matching of probe and control fields. We then show that spatially modulated control-field amplitudes allow us to coherently manipulate and compress the spatial shape of the stationary light pulse. These techniques can provide valuable tools for quantum nonlinear optics and quantum information processing.Comment: 27 pages, 10 figure

Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: Results from a large prospective cohort study

Introduction: Improvement of rheumatoid arthritis (RA) during pregnancy has been causatively associated with increased galactosylation of immunoglobulin G (IgG) N-glycans. Since previous studies were small, did not include the postpartum flare and did not study sialylation, these issues were addressed in the present study.Methods: Serum from 148 RA cases and 32 healthy controls was collected at several time points before, during and after pregnancy. Improvement during pregnancy and postpartum flare were determined according to the European League Against Rheumatism (EULAR) response criteria. Galactosylation and sialylation of Immunoglobulin G (IgG) and the presence of bisecting N-acetylglucosamine (GlcNAc) were analyzed by matrix-assisted laser desorption/ionization - time of flight - mass spectrometry (MALDI-TOF-MS).Results: IgG1 and IgG2 galactosylation of the cases and controls increased during pregnancy with a maximum in the third trimester. Galactosylation decreased directly postpartum. IgG galactosylation of controls was at a higher level than cases (P < 0.001 at all time points) and a similar pattern was observed for sialylation. Moreover, there was a good association between galactosylation and sialylation. The increase in galactosylation was significantly more pronounced for cases with improvement than cases without improvement during pregnancy. The reverse was true for deteriorators and non-deteriorators postpartum. The presence of bisecting GlcNAc was not significantly influenced by pregnancy or postpartum for c

Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women

BACKGROUND: Osteoporosis is a common disorder with a strong genetic component. One way in which the genetic component could be expressed is through polymorphism of COLIA1, the gene for collagen type Ialpha1, a bone-matrix protein. METHODS: We determined the COLIA1 genotypes SS, Ss, and ss in a population-based sample of 177

Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients

In the present study we describe the toxicity of weekly high-dose (70-85 mg m-2) cisplatin in 400 patients (203 men, 197 women; median age 54 years) with advanced solid tumours treated in the period 1990-2001 who took part in phase I/II trials, investigating the feasibility and efficacy of weekly cisplatin alone, or in combination with paclitaxel or etoposide. Cisplatin was administered in 250 ml NaCl 3% over 3 h, for six intended administrations. The mean number of administrations was 53 (range, 1-6 administrations). Reasons not to complete six cycles were disease progression (7.5%), haematological toxicity (9%), nephrotoxicity (7%), ototoxicity (2.5%), neurotoxicity (1%), gastrointestinal toxicity (1%), cardiovascular complications (0.5%) or a combination of reasons including noncompliance and patient's request (5.5%). Logistic regression analysis was used to evaluate baseline parameters for prognostic value regarding toxicity. Leukopenia correlated with etoposide cotreatment, and thrombocytopenia with cisplatin dose and prior (platinum-based) chemotherapy. Risk factors for nephrotoxicity were older age, female gender, smoking, hypoalbuminaemia and paclitaxel coadministration. Neurotoxicity >grade I (11% of patients) was associated with prior chemotherapy and paclitaxel coadministration. Symptomatic hearing loss occurred in 15% with anaemia as the predisposing factor. We conclude that weekly high-dose cisplatin administered in hypertonic saline is a feasible treatment regimen

Analysis of rare variants in the C3 gene in patients with age-related macular degeneration

Age-related macular degeneration (AMD) is a progressive retinal disorder affecting over 33 million people worldwide. Genome-wide association studies (GWASs) for AMD identified common variants at 19 loci accounting for 15-65% of the heritability and it has been hypothesized that the missing heritability may be attributed to rare variants with large effect sizes. Common variants in the complement component 3 (C3) gene have been associated with AMD and recently a rare C3 variant (Lys155Gln) was identified which exerts a large effect on AMD susceptibility independent of the common variants. To explore whether additional rare variants in the C3 gene are associated with AMD, we sequenced all coding exons in 84 unrelated AMD cases. Subsequently, we genotyped all identified variants in 1474 AMD cases and 2258 controls. Additionally, because of the known genetic overlap between AMD and atypical hemolytic uremic syndrome (aHUS), we genotyped two recurrent aHUS-associated C3 mutations in the entire cohort. Overall, we identified three rare variants (Lys65Gln (P = 0.04), Arg735Trp (OR = 17.4, 95% CI = 2.2-136; P = 0.0003), and Ser1619Arg (OR = 5.2, 95% CI = 1.0-25; P = 0.05) at the C3 locus that are associated with AMD in our EUGENDA cohort. However, the Arg735Trp and Ser1619Arg variants were not found to be associated with AMD in the Rotterdam Study. The Lys65Gln variant was only identified in patients from Nijmegen, the Netherlands, and thus may represent a region-specific AMD risk variant

Modelling Adaptation to climate change in agricultural systems

Modelling agricultural adaptation to climate change presents a range of challenges for modellers, but is vital to enabling decision makers to understand the potential costs and benefits of applying adaptation measures on-farm (or not) including risks and uncertainties associated with different actions. Here, the first stages of collaborative work undertaken at a workshop held in Braunschweig, Germany in autumn 2015, and subsequent analysis of findings, are reported. Subsequently, a second report will detail the development of these actions into a coherent overview of the state-of-the-art in modelling adaptation. Modellers and experimental researchers from a variety of disciplines (including biophysical and economic modellers from livestock, crop and grassland systems backgrounds) were asked to consider major climate impacts and associated adaptation options, and the challenges to modelling adaptations. Key modelling challenges fell into four main categories: information availability, accessibility of model outputs for stakeholders, technical challenges, and knowledge gaps. Within these categories, lists of specific challenges were compiled. The workshop revealed the diversity of approaches to modelling adaptation, and highlighted the different challenges associated with biophysical versus economic modelling. Understanding the state-of-the-art and key priorities for the modelling of climate change adaptation in agriculture is shown to be a complex and multi-faceted challenge. However, such an overview would provide a road map for stakeholder-driven improvement in modelling, with the potential to inform increased uptake of adaptation measures on-farm in Europe.(The main text will be published in a peer-reviewed journal